- Home
- OSUR vs BBOT Comparison
OSUR vs BBOT Comparison
Compare OSUR & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSUR
- BBOT
- Stock Information
- Founded
- OSUR 2000
- BBOT N/A
- Country
- OSUR United States
- BBOT United States
- Employees
- OSUR N/A
- BBOT N/A
- Industry
- OSUR Medical/Dental Instruments
- BBOT Biotechnology: Pharmaceutical Preparations
- Sector
- OSUR Health Care
- BBOT Health Care
- Exchange
- OSUR Nasdaq
- BBOT Nasdaq
- Market Cap
- OSUR 229.7M
- BBOT 250.4M
- IPO Year
- OSUR 1986
- BBOT N/A
- Fundamental
- Price
- OSUR $3.25
- BBOT $11.01
- Analyst Decision
- OSUR Hold
- BBOT Buy
- Analyst Count
- OSUR 1
- BBOT 2
- Target Price
- OSUR $3.00
- BBOT $24.00
- AVG Volume (30 Days)
- OSUR 590.2K
- BBOT 222.0K
- Earning Date
- OSUR 11-05-2025
- BBOT 01-01-0001
- Dividend Yield
- OSUR N/A
- BBOT N/A
- EPS Growth
- OSUR N/A
- BBOT N/A
- EPS
- OSUR N/A
- BBOT N/A
- Revenue
- OSUR $138,533,000.00
- BBOT N/A
- Revenue This Year
- OSUR N/A
- BBOT N/A
- Revenue Next Year
- OSUR $5.35
- BBOT N/A
- P/E Ratio
- OSUR N/A
- BBOT N/A
- Revenue Growth
- OSUR N/A
- BBOT N/A
- 52 Week Low
- OSUR $2.36
- BBOT $8.70
- 52 Week High
- OSUR $4.60
- BBOT $12.50
- Technical
- Relative Strength Index (RSI)
- OSUR 56.40
- BBOT N/A
- Support Level
- OSUR $3.12
- BBOT N/A
- Resistance Level
- OSUR $3.46
- BBOT N/A
- Average True Range (ATR)
- OSUR 0.16
- BBOT 0.00
- MACD
- OSUR 0.02
- BBOT 0.00
- Stochastic Oscillator
- OSUR 62.82
- BBOT 0.00
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.